Stephen Miller
Internal Medicine · Las Vegas, NVNPI 1871566448
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $414 and has fallen 96.6% since, to $14 in 2023.
Across 48 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$150
- Takeda Pharmaceuticals U.S.A., Inc.$136
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81
- Viiv Healthcare Company$71
- Pfizer$64
- Eisai Inc.$62
- plus $412 from 18 others
Across 34 payments — averaging $31,456 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$539K
- Pfizer$531K
What the payments were for
- Food & beverage$94196%
- Gifts$364%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 3 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Viiv Healthcare Company | 3 | $71 |
| Pfizer | 3 | $64 |
| Eisai Inc. | 4 | $62 |
| Novartis | 3 | $51 |
| GSK | 3 | $45 |
| Braintree Laboratories, Inc. | 1 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| AstraZeneca | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Electromed, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Mentor Worldwide LLC | 1 | $18 |
| Merck | 1 | $18 |
| Abbott | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| United Therapeutics Corporation | 1 | $15 |
| Gilead | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Apyx Medical Corporation | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE$122
How this compares
$976 in reported general payments places this provider in the 75th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.